Multiplicom Launches a New Test for the Diagnosis of CLL
Complete the form below to unlock access to ALL audio articles.
Multiplicom N.V. has announced the release of a new gene panel, the CLL MASTR™ Plus kit, to improve the diagnosis of patients with chronic lymphocytic leukemia. This is the most common form of leukemia in adults and has a highly variable outcome. Multiplicom’s test helps to steer the treatment options to stabilize the disease.
Chronic Lymphocytic Leukemia or CLL-patients can experience ‘stable disease’ - the cancer remains the same - over a prolonged period. But at any given time, CLL can progress very fast, requiring appropriate treatment adjustments to keep progression at bay.
Genetic analysis is an important tool in the differential diagnosis and distinguishes between ‘stable disease’ and ‘progression’. The CLL MASTR Plus kit is composed of 9 genes that are frequently mutated in CLL, providing information to guide treatment options.
The CLL MASTR Plus kit allows the detection of single nucleotide variants as well as copy number alterations. The identification of mutations in TP53, BIRC3, NOTCH1 and SF3B1 enables a more refined prognostic stratification, while the detection of TP53 mutations has therapeutic value as it guides treatment with alemtuzumab and/or steroids, which may be followed by allogeneic stem cell transplantation. This new test enables personalized medicine for patients with CLL.
“The composition of the gene panel was established in collaboration with key opinion leaders in the diagnosis and treatment of CLL. The CLL MASTR Plus kit is based on Multiplicom’s MASTR technology, delivering a simple, fast and affordable genetic test to labs. The MASTR kits are compatible with the leading NGS platforms, and have been subjected to state of the art quality control measures ensuring reproducible results” says Jurgen Del Favero, CTO of Multiplicom.
